←Back to all issuesIssue No. 02Regulatory5 min readMarch 2, 2026
The FDA reversal, explained
What the 2023 peptide ban was, why it happened, what changed in 2026, and what it means for you.
The FDA reversal, explained
What the 2023 peptide ban was, why it happened, what changed in 2026, and what it means for you.
|
The FDA reversal, explained
|
|
What the 2023 peptide ban was, why it happened, what changed in 2026, and what it means for you.
|
|
|
Dear Pru Community,
|
|
If you follow the peptide space, the past two and a half years have been disorienting. Therapies that clinicians had used safely for years vanished from licensed pharmacy shelves almost overnight. Patients turned to unregulated online suppliers. And then, in February 2026, the pendulum swung decisively in the other direction.
|
|
This issue explains exactly what happened to give you the clearest possible picture of a complex regulatory story. Because understanding the history matters if you want to understand where things stand today.
|
|
|
How compounding pharmacies work
|
|
Before getting to the ban, it helps to understand the legal framework. Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies are permitted to prepare customized medications for individual patients, including substances that have not gone through the FDA's full drug approval process, provided those substances appear on what is called the Bulk Drug Substances list.
|
|
The FDA maintains that list in three categories. Category 1 substances may be compounded under physician prescription while under FDA review. Category 2 substances have been identified as presenting significant safety risks and cannot be compounded. Category 3 substances lack sufficient data for evaluation. The classification of a compound determines whether a licensed pharmacy can legally prepare it for a patient at all.
|
|
|
The 2023 ban: what happened and why
|
|
In late 2023, the FDA moved 19 widely used therapeutic peptides from Category 1 to Category 2, effectively removing them from pharmacy shelves. The agency's stated rationale centered on three concerns: the risk of immunogenicity (the potential for injectable peptides to trigger immune reactions), the presence of manufacturing impurities in compounded preparations, and the absence of large-scale human clinical trial data for most of the affected compounds.
|
|
The compounds placed on the restricted list included some of the most clinically used peptides in regenerative medicine and longevity practice: BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Epithalon, GHK-Cu, Selank, Semax, KPV, MOTS-C, and others.
|
|
The FDA's rationale appeared to center on the absence of a U.S. New Drug Application rather than on any specific domestic safety signal. For many clinicians, that distinction was difficult to accept.
|
|
|
THE UNINTENDED CONSEQUENCE
|
|
When licensed compounding pharmacies could no longer legally supply these peptides, patient demand did not disappear. It moved to unregulated overseas vendors and "research use only" suppliers with no quality controls, no sterility guarantees, and no accountability. Independent testing of gray-market peptide products has found contamination, incorrect dosing, and in some cases entirely wrong compounds in the vial. As Kennedy himself acknowledged on the Rogan podcast, the restrictions "created the gray market." The ban produced the very safety problem it claimed to prevent.
|
|
|
|
The pushback: legal, clinical, and political
|
|
The 2023 restrictions were not accepted quietly. Clinicians, compounding pharmacists, and members of Congress argued the move was regulatory overreach unsupported by evidence of actual patient harm at scale. Evexias Medical Group and Farmakeio, a compounding pharmacy, filed suit against the FDA, arguing the agency had violated proper procedural standards in how it moved the compounds to Category 2. A legal settlement required the FDA to submit key peptides for review by the Pharmacy Compounding Advisory Committee, which held public meetings in late 2024.
|
|
|
February 27, 2026: the announcement
|
|
On that date, HHS Secretary Robert F. Kennedy Jr. appeared on The Joe Rogan Experience (Episode #2461) and announced that the FDA would be moving approximately 14 of the 19 restricted peptides from Category 2 back to Category 1, restoring their legal access through licensed compounding pharmacies under physician prescription. Kennedy framed the 2023 decision as lacking legitimate safety justification and said he hoped to see Americans gain access to these compounds "from ethical suppliers."
|
|
The announcement represented the most significant regulatory shift in peptide access since the original restrictions. For clinicians and patients who had spent two years navigating limited and unregulated supply, it was a long-awaited development.
|
|
|
What is actually changing and what is not
|
|
Several distinctions are worth holding clearly as this story develops. First, as of the time of writing, no formal FDA rulemaking has been published. Kennedy's announcement signals the direction but is not itself a regulatory action. Compounding pharmacies technically remain unauthorized to compound the Category 2 substances until an official Federal Register notice updates the Bulk Drug Substances list.
|
|
Second, reclassification to Category 1 is not FDA approval. These compounds would return to a state of being compoundable under physician supervision while remaining under FDA review. They are not approved drugs, and they do not have standardized dosing guidelines established through Phase III trials. They require a prescription, clinical evaluation, and ongoing monitoring.
|
|
Third, approximately five of the original 19 peptides are expected to remain on the restricted Category 2 list, including Melanotan II, GHRP-2, GHRP-6, Cathelicidin LL-37, and PEG-MGF, each of which carries either documented safety concerns or particularly limited human data.
|
|
|
The 14 peptides expected to return
|
|
While the official FDA list has not yet been published, the following reflects the informed consensus among regulatory analysts regarding which compounds are most likely to regain Category 1 status. These are not confirmed — treat them as the best available estimate pending formal publication.
|
|
|
HEALING & RECOVERY
BPC-157 · TB-500 · Thymosin Beta-4
|
|
IMMUNE & THYMIC
Thymosin Alpha-1 · KPV · Thymalin
|
|
GROWTH HORMONE
Ipamorelin · CJC-1295 · AOD-9604
|
|
COGNITIVE & NEUROLOGICAL
Selank · Semax · DSIP
|
|
LONGEVITY & CELLULAR
Epithalon · GHK-Cu · MOTS-C
|
|
LIKELY REMAINING RESTRICTED
Melanotan II · GHRP-2 · GHRP-6 · LL-37 · PEG-MGF
|
|
|
|
This table reflects informed regulatory analysis as of April 2026. It does not represent an official FDA list, which has not yet been published. Always confirm current status with your Pru provider before beginning or adjusting any protocol.
|
|
|
|
What this means for Pru members
|
|
Pru was built to operate within the regulated system, not around it. We source exclusively from licensed, accredited U.S. compounding pharmacies that comply with USP 797 and 795 sterility standards and provide certificates of analysis for every batch.
|
|
As formal reclassification is published, our formulary will expand. We will communicate clearly and directly with members as specific compounds become available through compliant channels. No protocol at Pru is adjusted without clinical review — your provider will evaluate your current labs, goals, and health history before any change is made.
|
|
If you have questions about a specific peptide and where it currently stands, the best starting point is a direct conversation with your Pru clinician. This is a developing situation, and we are watching it closely on your behalf.
|
|
|
WORTH READING
|
|
ProPublica (2026, April). "RFK Jr. May Reverse a Peptide Ban He Calls Illegal. Former FDA Officials Say He Mischaracterized Their Work." A carefully reported piece presenting the full regulatory history — worth reading for anyone who wants the complete picture.
|
|
|
Want more like this?
Subscribe to get new issues delivered to your inbox. No spam, unsubscribe anytime.